Financial Performance - The company's revenue for Q1 2025 was ¥128,727,480.49, a decrease of 40.32% compared to ¥215,702,841.54 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥26,197,617.81, representing a decline of 152.59% from a profit of ¥49,818,209.14 in the previous year[4]. - Total operating revenue for the current period was ¥128,727,480.49, a decrease of 40.4% compared to ¥215,702,841.54 in the previous period[18]. - Net profit for the current period was a loss of ¥26,197,617.81, compared to a profit of ¥49,818,209.14 in the previous period, representing a significant decline[19]. - Basic and diluted earnings per share for the current period were both -¥0.24, compared to ¥0.46 in the previous period[20]. - Other comprehensive income after tax for the current period was -¥32,349.31, compared to -¥1,349.85 in the previous period[19]. Cash Flow - The net cash flow from operating activities improved by 42.59%, amounting to -¥70,028,927.58 compared to -¥121,975,608.72 in the prior year[4]. - The company reported a total of ¥108,725,148.09 in cash inflows from operating activities, a decrease from ¥110,905,629.87 in the previous period[21]. - Investment activities generated cash inflows of ¥128,032,273.42, compared to ¥97,926,542.60 in the previous period, indicating a positive trend in investment recovery[21]. - Net cash flow from investment activities was -233.07 million in the previous period[22]. - Cash inflow from financing activities totaled 514 million in the prior period[22]. - Cash outflow for debt repayment was 249.50 million previously[22]. - The net increase in cash and cash equivalents was -93.80 million in the previous period[22]. - The ending balance of cash and cash equivalents was 684.65 million at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,773,885,876.81, reflecting a 1.42% increase from ¥3,721,188,515.50 at the end of the previous year[4]. - Current assets totaled CNY 1,610,431,297.78, up from CNY 1,545,474,358.29 at the start of the period, reflecting a growth of approximately 4.9%[14]. - Total liabilities rose to CNY 1,220,726,059.65 from CNY 1,141,798,731.22, reflecting an increase of about 6.9%[15]. - The company's equity remained stable with total equity at CNY 2,553,159,817.16, consistent with previous periods[15]. - The company reported a significant increase in contract assets, which rose to CNY 390,159,165.61 from CNY 379,655,510.32, indicating a growth of approximately 2.6%[14]. Expenses - The company experienced a 368.22% increase in financial expenses, totaling ¥3,443,240.34, primarily due to increased loan amounts and interest expenses[8]. - Total operating costs increased slightly to ¥164,765,613.68 from ¥164,553,615.62, with operating costs rising to ¥75,155,234.89 from ¥68,611,172.02[18]. - Research and development expenses decreased to ¥54,466,161.55 from ¥65,271,951.41, indicating a reduction in investment in innovation[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,188, with no preferred shareholders[10]. Government Support - The company received government subsidies amounting to ¥8,473,176.69, contributing to other income growth of 634.24%[8]. Return on Equity - The company's weighted average return on equity decreased to -1.02% from 1.84% in the previous year[4].
百诚医药(301096) - 2025 Q1 - 季度财报